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380August 30, 2014. Both TEE and TTE were performed
with the use of a Vivid 9 imaging platform (GE
Healthcare, Waukesha, Wisconsin). Valve sizing was
determined by means of multidetector computed to-
mography. Fluoroscopic guidance was used in all
cases. Anesthesia was administered and monitored by
a cardiac anesthesiologist. General anesthesia con-
sisted of tracheal intubation facilitated with a para-
lytic and induction agent. Anesthesia was maintained
with inhaled anesthetics and intravenous opioids.
MAC was administered with the use of infusions of
either dexmedetomidine or propofol in combination
with intravenous opioids and local anesthesia (2.0%
lidocaine with 0.5% bupivacaine) applied to the
femoral access site. Both cohorts were monitored
with insertion of a central venous catheter, pulmo-
nary artery catheter, temporary right ventricular
pacemaker, and invasive arterial blood pressure
catheter. The 2 groups were compared by use of
standard statistical methods for continuous and cat-
egorical variables, with differences considered sta-
tistically signiﬁcant at p < 0.05.
The study population included 111 patients, of
whom 64 underwent TAVR with TEE (GA) and 47
underwent TTE (MAC). The Edwards-SAPIEN THV
(Edwards Lifesciences, Irvine, California) was placed
in 50 of the TEE cohort and in 9 of the TTE cohort. The
remainder of the patients received the CoreValve
prosthesis. Two patients in the TTE cohort were
converted to TEE because of inadequate transthoracic
windows. The baseline characteristics are presented
in Table 1.
Outcome data were statistically similar between
the cohorts with regard to procedural success, degree
of paravalvular regurgitation, need for additional
valve implantation, or complications such as peri-
procedural stroke or death (Table 1). Procedural time
was longer in the TEE (GA) cohort (p < 0.001) and
related to the time needed for weaning off the
ventilator. The median length of stay was 6 days in
both groups and was not affected by type of valve.
The similar length of stay was related to our institu-
tional policy that required monitoring for 48 h in the
intensive care unit, irrespective of the type of anes-
thesia or valve implanted.
Although this is a retrospective study with a
modest sample size and relative heterogeneity with
respect to type of valve implanted, our data suggest
that TAVR can be safely performed with the use of
TTE guidance under MAC. These ﬁndings require
larger, prospective, multicenter studies to more
clearly deﬁne potential beneﬁts such as shorter pro-
cedural times, decreased length of stay, and reduced
hospital costs.Partho P. Sengupta, MD*
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analysis. BMC Med 2014;12:41.Dobutamine Stress Echocardiography for
Risk Stratiﬁcation of Patients With
Low-Gradient Severe Aortic Stenosis
Undergoing TAVRPatients with low-gradient severe aortic stenosis
(LGSAS) have dismal outcomes when medically
managed and although their long-term outcomes are
improved with surgery, their risk of death is signiﬁ-
cantly higher than that of their counterparts with
mean transaortic gradient (DP) >40 mm Hg (1). Low-
dose dobutamine stress echocardiography (DSE), by
determining whether ﬂow reserve (FR) is present
with inotropic stimulation, has proven useful in
enhancing risk stratiﬁcation of this high-mortality
subgroup undergoing surgical aortic valve replace-
ment (SAVR) (2,3). Whether the lack of FR in patients
undergoing transcatheter aortic valve replacement
(TAVR) similarly portends poor prognosis is unknown
and was explored in this study.
Electronic medical records of patients who under-
went TAVR for severe AS at Emory University
Hospital from January 2009 to March 2013 were
reviewed. Demographics and clinical characteristics
including comorbidities, outcomes, and echocardio-
graphic data were retrospectively collected. LGSAS
was deﬁned as DP <40 mm Hg and an aortic valve
area (AVA) #1.0 cm2, with either reduced or normal
ejection fraction (EF) on baseline transthoracic
echocardiogram. Forty-nine patients with LGSAS who
FIGURE 1 Kaplan-Meier Survival Curves of Patients With
Low-Gradient Severe Aortic Stenosis With and Without
Flow Reserve
Kaplan-Meier survival curves of patients with low-gradient aortic
stenosis who underwent dobutamine stress echocardiography;
stratiﬁed by ﬂow reserve (FR) (þFR: stroke volume index [SVI]
>20%, n ¼ 22; FR: SVI <20%, n ¼ 27).
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381underwent DSE before TAVR were identiﬁed. DSE was
not performed routinely in the evaluation of all
patients with LGSAS, and these speciﬁc patients had
undergone DSE to exclude pseudo–severe AS. The
following parameters were collected at baseline and
peak dobutamine infusion: EF, AVA, mean and
peak aortic transvalvular gradients, left ventricular
outﬂow tract diameter, and velocity-time integral
(VTI). In patients with atrial ﬁbrillation, VTI was
measured as the mean value of 5 cardiac cycles. FR
was deﬁned as a 20% increase in stroke volume index
(SVI) from rest to peak dobutamine infusion. All
patients completed DSE successfully. All-cause
mortality was determined by chart review, phone
communication with the patient or next of kin, and
searches of the Social Security Death Index. Survival
curves were presented as Kaplan-Meier curves, and
the log-rank test was used for comparison between
groups. Multivariable analysis using Cox proportional
hazards model was performed for all-cause mortality.
The study was approved by the Emory University
Institutional Review Board Committee.
Overall, the cohort consisted of mostly elderly (age
808 years), white (88%)men (70%). All patientswere
treated with a SAPIEN transcatheter heart valve
(Edwards Lifesciences, Irvine, California) via either
the transfemoral (60%) or transapical approach (40%).The mean EF at baseline was 38  14%, with 77% of
patients with EF <50%. Median follow-up time was 14
months (interquartile range: 8 to 24). Twenty-seven
patients (55%) did not have FR, with an average in-
crease in SVI of 5  11%, compared with 45  26% for
those with FR (p < 0.001). Patients without FR had a
higher prevalence of chronic obstructive pulmonary
disease (COPD) (63% vs. 32%; p ¼ 0.030); otherwise,
clinical characteristics were similar. At the time of
data collection, there had been 16 deaths, of which
13 (81%) were patients without FR. Patients without
FR had worse short- and intermediate-term survival
compared with those with FR (Figure 1). Two patients
without FR (7%) and no patients with FR died during
the initial hospitalization. Thirty-day mortality was
21% versus 5%, 1-year mortality 30% versus 9%, and
2-year mortality 46% versus 26% compared with those
with FR (p < 0.001). Univariable analysis with Cox
regression identiﬁed COPD (hazard ratio [HR]: 1.77;
p ¼ 0.052), female sex (HR: 1.83; p ¼ 0.034), and
SVI<20% (HR: 3.70; p¼0.041) as signiﬁcant predictors
of all-cause death. In multivariable analysis including
sex and COPD, SVI <20% remained an independent
predictor of mortality (HR: 4.47; p ¼ 0.037).
This study is the ﬁrst to describe the use of FR
derived by DSE in the risk stratiﬁcation of patients
with LGSAS undergoing TAVR. The subgroup of pa-
tients with LGSAS who failed to achieve a 20% in-
crease in SVI with dobutamine infusion had worse
short- to intermediate-term mortality compared with
those with FR. These ﬁndings echo the difference in
outcomes in similar subgroups of patients with AS
undergoing SAVR (1–3). Thus, despite the avoidance
in TAVR of ischemia-reperfusion injury and myocar-
dial stunning induced by cardiopulmonary bypass
and cardioplegia during SAVR, patients without FR
still have increased mortality. Despite being at higher
surgical risk, these patients have post-procedural
outcomes similar to those of lower-risk patients who
undergo SAVR. Prospective studies comparing out-
comes after SAVR and after TAVR in similar surgical
risk patients without FR are needed to deﬁne a clin-
ically useful role for DSE before TAVR.Salim Hayek, MD
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FIGURE 1 Potentia
With Severe Aortic
AVR ¼ aortic valve re
strain; LF¼ lowﬂow;
gradient; NF¼norma
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and Valve GuidelinesThe review by Galli et al. (1) provides an important
overview of left ventricular mechanics in common
valvular diseases. At the same time, for a practicing
cardiologist it is important that this information isl Role of Global Longitudinal Strain in the Management of Patients
Stenosis According to Flow-Gradient Pattern
placement; ETT ¼ exercise testing; GLS ¼ global longitudinal
LG¼ lowgradient; LVEF¼ left ventricular ejection fraction;MG¼mean
lﬂow;NG¼normal gradient; SVI¼ stroke volume index; Vel¼velocity.presented in the context of the current valvular dis-
ease guidelines to highlight the areas where clinical
decision making can be augmented by this additional
information (2). As a relevant example, the algorithm
for the management of patients with severe aortic
stenosis (Figure 8 in Galli et al. [1]) is confusing. An
alternative diagram is presented in Figure 1 which
integrates the current guidelines with evolving
knowledge as well as highlights important gaps. The
normal ﬂow/low gradient group is not properly
deﬁned because the guidelines prioritize the velocity/
gradient approach over the aortic area measurement.
In these cases careful measurement veriﬁcation is
important, such as obtaining proper outﬂow tract area
and indexing valve area to body surface area. Also,
one should bear in mind that in a normal ﬂow state a
mean gradient of 40 mm Hg corresponds to an aortic
valve area of <0.8 cm2, so there is inherent discrep-
ancy with the old deﬁnition of severe aortic stenosis
(valve area of <1 cm2) (2). In this challenging group,
longitudinal strain measurement and calcium scoring
may provide valuable information. In the groups of
patients with high gradients regardless of ﬂow state,
the guidelines are mostly explicit and unequivocal.
In the low ﬂow/low gradient group, left ventricular
ejection fraction (LVEF) is an important deﬁning
factor. Patients in this group who have decreased
LVEF should probably undergo dobutamine infusion
to identify true severe stenosis and assess contractile
reserve. Patients in the low ﬂow/low gradient group
with normal LVEF need repeat measurements after
adequate blood pressure control and they may also
beneﬁt from longitudinal strain measurement and
calcium scoring. Unlike the recommendation by Galli
et al. (1), dobutamine infusion is not supported by
substantial evidence in this subgroup (2).Edgar Argulian, MD, MPH*
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